3-hydroxy Anthranilic Acid (Synonyms: 3-HAA,NSC 522891) |
| カタログ番号GC13377 |
3-ヒドロキシ アントラニル酸は、キヌレニン経路のトリプトファン代謝産物です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 548-93-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
3-Hydroxyanthranilic acid (3-HAA) is an intermediate in the metabolism of the amino acid tryptophan. 3-HAA is an aminobenzoic acid generated by substitution of benzoic acid at C-2 with an amine group and at C-3 by a hydroxy group. 3-Hydroxyanthranilic acid is a new antioxidant isolated from methanol extract of tempeh [1].
Tryptophan metabolism by the kynurenine pathway (KP) plays an important role in the pathogenesis of inflammatory, infectious, and degenerative diseases [2]. 3-HAA effectively suppressed glial cytokine and chemokine expression and reduced cytokine-induced neuronal death [2]. In astrocytes, 3-HAA induced the expression of hemeoxygenase-1 (HO-1), an antioxidant enzyme with anti-inflammatory and cytoprotective properties. In cultured adult human astrocytes, 3-HAA induced HO-1 expression, which has also been observed after injection to mouse brains [2]. 3-HAA acted as a co-antioxidant for α-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation [3]. 3-HAA inhibited nitric oxide (NO) synthase in macrophages and stimulated TGF-β production, suppressing pro-inflammatory activity of Th1 cells [1].
References:
[1] Stone T W, Stoy N, Darlington L G. An expanding range of targets for kynurenine metabolites of tryptophan[J]. Trends in pharmacological sciences, 2013, 34(2): 136-143.
[2] Krause D, Suh H S, Tarassishin L, et al. The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1[J]. The American journal of pathology, 2011, 179(3): 1360-1372.
[3] Thomas, S. R.,Wittig, P.K. and Stocker, R. 3-Hydroxyanthranilic acid is an efficient, cell-derived co-antioxidant for α-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation. The Journal of Biological Chemisty 271, 2714-32721 (1996).
| Cas No. | 548-93-6 | SDF | |
| 同義語 | 3-HAA,NSC 522891 | ||
| Chemical Name | 2-amino-3-hydroxy-benzoic acid | ||
| Canonical SMILES | OC(C1=C(N)C(O)=CC=C1)=O | ||
| Formula | C7H7NO3 | M.Wt | 153.1 |
| 溶解度 | ≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.5317 mL | 32.6584 mL | 65.3168 mL |
| 5 mM | 1.3063 mL | 6.5317 mL | 13.0634 mL |
| 10 mM | 0.6532 mL | 3.2658 mL | 6.5317 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *